Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
October 2021
-
Media ReleaseNovartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccineAt least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia New…
-
Media ReleaseGlobal Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killerInvisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (…
-
Media ReleaseKesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosisALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there…
-
Featured NewsWorld Sight Day 2021
Novartis is working with partners around the world to help eliminate preventable visual impairment and blindness by reimagining access to eye care.
-
Restoring vision and hope to thousands in Southeast Asia
Eyesight initiatives are restoring vision – and hope – to thousands of people in Southeast Asia by expanding equitable access to eye care.
-
Media ReleaseNovartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edemaRegulatory decisions for Beovu (brolucizumab) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed…
-
Media ReleaseSandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibioticsSandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading…
-
Expanding a new digital healthcare solution across chronic heart disease management
More than 100,000 patients with heart failure in China are using our new AI-enabled platform, AI Nurse, to manage their condition and aim for better health.
-
Media ReleaseNovartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosisNovartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)Novartis will be commencing Phase III…
-
Media ReleaseSandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic DrugsCompany previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz,…
-
StatementEnabling our associates to work safely on our sites
Pagination
- ‹ Previous page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- …
- 151
- › Next page